Intercept Pharma (ICPT) Misses Q4 EPS Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil prices, producer inflation ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Wedbush Cuts PT on Intercept Pharma (ICPT) to $423, Remains Bullish
February 24, 2016 8:17 AM ESTWedbush analyst, Liana Moussatos, reiterated her Outperform rating on shares of Intercept Pharma (NASDAQ: ICPT) and thinks there will be a buying opportunity ahead of the release of AdComm briefing documents on April 7th. Acquisition value drops to $423 from $493 as expectations for the NASH launch are pushed to late19 from H1:18.
Intercept reported Q4 / FY revenues of $0.45MM / $2.78MM on GAAP EPS of $(3.62) / $(9.56) vs. consensus revenues est. of... More
